DHANLYRA
Live / Applied — Suspended — suspension letter mailed (as of 02 Mar 2026)
What this means for you
Not registered yet, but its 10 Oct 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99436221
- Mark type
- Stylized text
- Filed
- 10 Oct 2025
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Anti-inflammatories; Cardiovascular pharmaceuticals; Pharmaceutical preparations for the treatment and prevention of inflammatory diseases and disorders; Pharmaceutical preparations for the treatment and prevention of autoimmune diseases and disorders; Pharmaceutical preparations for the treatment and prevention of cardiac diseases and disorders; Pharmaceutical preparations for the treatment and prevention of immune-mediated diseases and disorders;; Pharmaceutical preparations for the treatment and prevention of rare diseases and disorders
Owner
- Kiniksa Pharmaceuticals, GmbH, Zug, CH
Prosecution history
- 10 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 Mar 2026 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 02 Mar 2026 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 02 Mar 2026 — LETTER OF SUSPENSION E-MAILED
- 02 Mar 2026 — SUSPENSION LETTER WRITTEN
- 27 Feb 2026 — ASSIGNED TO EXAMINER
- 10 Oct 2025 — APPLICATION FILING RECEIPT MAILED
- 10 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 10 Oct 2025 — NEW APPLICATION ENTERED